See every side of every news story
Published loading...Updated

Unlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins

Summary by digitaltwininsider.com
SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a leader in AI solutions for clinical trials, today announced results from a collaboration with remynd, a Belgium-based biotech company developing treatments for neurodegenerative diseases. The results were shared at the 2025 Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The collaboration focused on remynd’s Phase 2a clinical trial of REM127, an investigational, first-gener…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

digitaltwininsider.com broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.